Inventurus Knowledge Solutions Limited has informed the Exchange regarding that the Board of Directors of the Company at its meeting held today, i.e., July 31, 2025, inter alia, approved the matters stated in the attached disclosure.

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

IKS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.1%Reaction day

₹1594.00

prior close

₹1649.90

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.6%+1.5% vs market

IT Enabled Services peers, median of 63sector-0.7%+0.6% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Smallcap 250 and 0.6 pts more than its IT Enabled Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.1

10m

-5.3

15m

-6.1

30m

-5.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.1-1.6+1.5-0.7+0.6

Next day

-1.4-0.7-0.7-0.9-0.5

-1.4-1.0-0.4-0.8-0.5

-0.3-2.2+1.9-2.4+2.2

+1.9-2.3+4.2-1.6+3.6

+0.4-3.5+3.9-2.5+2.9

-2.9-3.1+0.2-1.9-1.0

15d

+0.4-0.5+0.9-1.9+2.3

-5.3-2.4-2.9-1.3-4.0

-6.8-1.6-5.2-2.8-4.0

+2.3+1.7+0.6-1.0+3.3

UpDownMarket · Nifty Smallcap 250Sector · IT Enabled Services peers, median of 63Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Inventurus Knowledge Solutions (IKS Health) announced strong Q1 FY26 results on July 31, 2025. Consolidated revenue from operations rose to ₹7,400.95M from ₹6,400.93M in Q1 FY25 (~15.6% growth), while consolidated profit after tax jumped to ₹1,515.39M from ₹954.87M (~58.7% growth). Standalone revenue surged to ₹3,194.69M from ₹2,013.75M (~58.6% growth) with PAT at ₹1,128.75M vs ₹572.02M (~97% growth). Basic EPS nearly doubled to ₹9.07 from ₹5.75 on a consolidated basis. The board approved multiple leadership changes effective August 1, 2025: founder Mr. Sachin Gupta stepped down as Whole-time Director (citing personal reasons) and was redesignated as Non-Executive, Non-Independent Director while also being named Global CEO of the US subsidiary. CFO Ms. Nithya Balasubramanian was elevated to Whole-time Director for a 5-year term. Dr. Garheng Albert Kong (founder of HealthQuest Capital) joined as Independent Director. KKC & Associates LLP was re-appointed as Internal Auditor for FY 2025-26.

Likely market impact

The strong earnings beat—especially the ~58% consolidated PAT growth and significant margin expansion—should support positive sentiment. The leadership transition looks orderly: a founder-led exit from executive role is balanced by elevation of the CFO and addition of a high-profile US healthcare investor as independent director, signalling strategic focus on US healthcare expansion (consistent with the recent ~$17M acquisition of a 48% stake in IKS WWMG MSO LLC).